Deficiency Letter of All Deferred Products in 91st Meeting of EEC Held On 13 07 2021

F.No.
10-07/2021-OTC) (M-91)
Government of Pakistan
Ministry of National Health Services, Regulations & Coordination
Drug Regulatory Authority Of Pakistan
Health & OTC Products Division (Non-Drugs)
*****
Islamabad, the 21st October, 2021
“SAY NO TO CORRUPTION”
Subject: Submission of deficient information / documents

The applications of following applicants were placed before the Enlistment Evaluation
Committee (EEC) in its 91st meeting held on 13th July, 2021 and the same have been deferred being deficient
of the information / documents as specified in column (3) of the Table below which may be furnished within
20 days of uploading of this letter on official website of DRAP along with soft data as per Annexed Format at
the end of this letter/document. Replies received after given time will not be entertained:-
S.No Brand name Decision
(1) (2) (3)
M/s New Altaf Dawakhana,
Near Railway Canal Bridge, Mianwali (E. No. 00792)
1. Libido Booster Capsule Deferred for change of brand name
2. Male Super Enhancement Capsule Deferred for change of brand name
M/s. Arshzik (Veterinary),
23 Km Near Al-Ghani CNG, G.T. Road, Rawat, Rawalpindi (E. No. 00302)
Deferred for the mrmon tea extract which is common name of
3. Flunzatech HRe Oral Liquid
Ephedra a controlled substance / precursor
Deferred for the mrmon tea extract which is common name of
4. Flunzatech HRe Oral Liquid
Ephedra a controlled substance / percusrsor
M/s Salbion Health Sciences (Pvt) Ltd.,
23-Km, Sheikhupura Road, Lahore-Pakistan (E. No. 00647)
5. Ovifertil Tablet Deferred for clarification of each two tablets
M/s Labbaik Herbal Pharma,
Plot No. 122, Phase-II, M-3 Industrial Estate, Sahianwala, Faisalabad (E. No. 01182)
EEC decided to defer the application for enlistment for the change
6. LABBAIK AKSEER BAWASEER TABLET
of brand name.
7. LABBAIK IRON TABLET
of brand name.
8. HUBB-E-PAICHAS TABLET
of brand name.
EEC decided to defer the application for due to following reasons:
9. LABBAIK HUBB E ATTHRA TABLET  Brand name needs to be changed.
 Provide monographs of Citrullus lanatus and mother pearl
10. LABBAIK KHAMEERA GAOZUBAN SADA
of brand name.
11. LABBAIK AKSEER BAWASEER CAPSULE
of brand name.
12. LABBAIK TOLEED E SPERM CAPSULE
of brand name.
EEC decided to defer the application for enlistment due to
following reasons:
 Brand name needs to be changed.
13. LABBAIK PERFECT MUGHALIZ CAPSULE
 Justify the use of following homoeopathic ingredients in
herbal formulation: “Dipterex odorata (HPI) and Stanum
mettalicum (HPI)”.
Page 1 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
 Provide undertaking regarding submission of stability data
of the applied formulation on company’s letter head duly
signed by the owner of the firm.
14. LABBAIK EZEDAYS CAPSULE
of brand name.
15. LABBAIK ALSIRON CAPSULE
of brand name.
16. LABBAIK CHOLESTEROL CAPSULE
of brand name.
17. LABBAIK VITA SKIN CAPSULE
of brand name.
18. LABBAIK HARMAIN PHAKKI
of brand name.
19. LABBAIK SAFOOF TOLEED E SPERM
of brand name.
20. LABBAIK SAFOOF ALSAR
of brand name.
21. LABBAIK LAZEEZ CHURAN
of brand name.
22. LABBAIK SAFOOF KIDNEY CARE
of brand name.
23. LABBAIK AREENA HAIR OIL
of brand name.
24. LABBAIK AMLA OIL
of brand name.
25. LABBAIK ROGHAN DARD
of brand name.
26. LABBAIK ROGHAN USHNA
of brand name.
following reasons:
27. LABBAIK PIPRAMINT SYRUP
 Mention individual strengths of each ingredient being
used in the formulation accordingly revise form-3.
following reasons:
 Justify the use of applied product as herbal/unani
28. LABBAIK SANDUR MARHAM alternative medicine.
 Provide evidence of competitor of applied formulation as
herbal/unani alternative medicine.
 Provide monograph of sandur.
29. LABBAIK BAWASEERI MARHAM
of brand name.
M/s Winns International,
30-M Industrial Area, Kot Lakhpat, Lahore (E. No. 01165)
30. VIGORWIN CAPSULE
of brand name.
31. WINSLIM CAPSULE
of brand name.
32. MYOWIN CAPSULE
of brand name.
following reasons:
33. WINSONATE SACHET
 The applied formulation contains Ossein Mineral
Compolex which is a common molecule.
following reasons:
34. KARNILOX LIQUID
 Provide evidence regarding unit dose filling and sealing
machines of oral liquids sachet/ stick.
Page 2 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
 EEC decided to defer the application for enlistment for the
35. GESRID SYRUP
change of brand name.
following reasons:
36. E - WIDE DROPS  Form-3 needs to be revised w.r.t. mentioning the “IU per
ml” strength of active ingredient, keeping in view the
Recommended daily allowance of vitamin E.
following reasons:
37. A - WIN DROP
 Form-3 needs to be revised w.r.t. mentioning the “IU per
Recommended daily allowance of vitamin A.
following reasons:
 The firm applied same formulation with insignificant
38. D - BONE DROPS difference, need clarification.
Recommended daily allowance of vitamin D3.
following reasons:
39. D 5 DROPS difference, need clarification.
following reasons:
40. D - BONE 6 DROPS difference, need clarification.
following reasons:
41. D - BONE PLUS DROPS difference, need clarification.
following reasons:
42. AD PLUS DROPS
ml” strength of active ingredients, keeping in view the
Recommended daily allowance of vitamin A, D and E.
43. BIOWIN GEL
of brand name.
44. BIOWIN PLUS GEL
of brand name.
following reasons:
45. CAPSIWIN LOTION  Brand name needs to be changed.
 Form-3 needs to be revised w.r.t. mentioning the exact
name of each ingredient as per monograph.
46. DERMA WIN LOTION
Page 3 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
following reasons:
47. PAIN WIN PLUS CREAM  Brand name needs to be changed.
 Form-3 needs to be revised w.r.t. mentioning the exact
name of each ingredient as per monograph.
48. PAIN WIN CREAM
of brand name.
49. WINNS’S VAPOURUB
of brand name.
50. WINNS’S VAPOURUB PLUS
of brand name.
M/s Pasteur & Fleming Pharmaceuticals Pvt. Ltd.,
Plot No. P-70-A, Road No.4, Phase-III, Industrial Estate, Hattar (01188)
51. FLUWEL SYRUP
of brand name.
Leads Nutraceutical,
Plot No. 81-A, Street No. 6, Industrial Area, Sector I-10/3, Islamabad (E. No. 01190)
EEC decided to defer the application for enlistment on following
reasons:
 Provide specification of each ingredient.
 Specify the type of Vitamin K, Antioxident, 6-phytase and
52. Multivit Phytase Granules
Vegetable proteins being used in the formulation and provide
relavant monographs.
 Mention salt of each elemental ingredient.
 Provide all undertakings (Notarized stamp paper).
Falcon Laboratories (Pvt.) Limited, (E. No.00710)
Special Industrial Estate, Behind Industrial Estate Office Risalpur, Nowshera
53. Kufsim Syrup
of brand name.
following reasons:
54. PEDIFAL ORAL REHYDRATION SOLUTION
 The firm applied ORS (Oral Rehydration Solution) which
is added in the list of common molecules.
Falcon’s EEC decided to defer the application for enlistment for the change
55.
Femcare Capsule of brand name.
56.
Neurocalm Capsule of brand name.
following reasons:
57. APELYTE Sachet
 The firm applied ORS formulation which is added in the
list of common molecules.
58. FETOSLIM SACHET
Falcon’s  EEC decided to defer the application for enlistment for the
59.
Bonyfal Tablet change of brand name.
60.
Cufsils Chewable Tablet of brand name.
61.
Hepacare Tablet of brand name.
M/s. Gold Sheff International Nutraceutical,
537-F, Sunder Industrial Estate (PIE), Raiwind Road, Lahore
62. Calcigold Sachet
of brand name.
63. Calcimax Sachet
of brand name.
64. Calcip Sachet
of brand name.
65. Calciway Sachet
of brand name.
Page 4 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
66. Econil Sachet
of brand name.
67. Femis Sachet
of brand name.
68. Urimac Sachet
of brand name.
69. Proseed Sachet
of brand name.
70. Carnizym Sachet
of brand name.
Faran Pharmcy, Lahore
EEC decided to deferred the application for enlistment due to
following reasons:
 Final opportunity for submission as The applied
71. Asterias Rubens Potency
formulation contains sarcodes and evidence required that
source should be free from TSE,BSE,Ecoli and
Salmonella
EEC decided to deferred the application for enlistment due to
following reasons:
 Final opportunity for submission as The applied
72. Bufo Rana Potency
formulation contains sarcodes and evidence required that
source should be free from TSE,BSE,Ecoli and
Salmonella
EEC decided to deferred the application for enlistment on following
ground:
73. Formica Rufa Potency  The applied formulation contains sarcode and source
evidence that’s its should be free from TSE,BSE,Eoli and
salmonella
EEC decide to deferred the application for enlistment due to
following reasons:
74. Insulin Potency  The primary source of insulin is required
 The handling,preparation and storage facilities are
required
EEC decide to deferred the application for enlistment due to
following reasons
75. Lachesis Potency  The applied formulation contains sarcodes and evidence
that source should be free from TSE,BSE,ecoli and
salmonella
EEC decide to defer the application for enlistment on following
grounds:
76. Tarentula Hispanica Potency
 the applied formulation contains sarcodes and source
evidence should be free from TSE,ecoli salmonella
EEC Decided to defre the application for enlistment on following
grounds
77. Blatta Orientalis-Q Mother Tincture
EEC Decided to defre the application for enlistment on following
grounds
78. Cantharis-Q Mother Tincture
grounds:
79. Coccus Cacti Potency
 the applied formulation contains sarcode and source
evidence should be free from TSE,ecoli and salmonella
80. Fel Tauri Potency grounds:
 source should be free from TSE,Ecoli and salmonella
81. Lac Canium Potency
grounds:
Page 5 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
EEC decide to defer the application for enlistment om following
82. Latrodectus Mactans Potency grounds:
EEC decided to defre the application for enlistment for following
grounds:
83. Trombidium Potency
 source should bre free from TSE,BSE, ecoli and
salmonella
EEC decided to defer the application for enlistment for following
84. Adrenlinum Potency grounds:
 source should be free from TSE,ecoli and salmonella
85. Pancreatinum Potency grounds:
86. Pituitarinum Potency grounds:
87. Thyroidinum Potency grounds:
Alfalah Health Care (Pvt) Ltd Lahore
EEC was apprised that division undertook a big task of company
wise arrangement of applications in various designated racks. Since
computerization of record of submitted applications and subsequent
preparation of their FIFO list, the division has been evaluating and
processing files.Hence,there are chances that some product
88. Okci Plus Syrup
applications were disposed of but still their names are available in
the FIFO list. Accordingly,EEC appreciated the services of division
of health and OTC and decided to defer decision of the instant
product application to check its status whether it has been disposed
of or otherwise.
89. Fabize Syrup
of or otherwise.
Alpha Nutraceutical, Lahore
grounds:
 Clarification regarding a product either applied product is
90. Bolac Syrup
herbal or Nutraceutical
 Fee paid for herbal product remaining fee of 1750 rupees
in case of nutraceutical product
Angel Human Health Nutraceutical, Faisalabad
91. Notis Tablet
of or otherwise.
Page 6 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
92. Multiaim Tablet
of or otherwise.
93. Aim Fer Syrup
of or otherwise.
94. Q-Vit Tablet
of or otherwise.
Animal Life Care, Bahawalpur
grounds:
 Properly filled signed and stamped form 3 is required
 Form 3 needs to be revised w.r.t showing specification of
active
ingredients in formulation
brand name needs to be changed
95. Masti Care Liquid According to NOTIFCATION F.NO.4-2/2017-DD(H&OTC) in
para (2)following information is required in support of the claim of
availability of the proposed combination in local market for last
10years,
 Company/firm establishment documents
 Sales invoices including distribution record
 Undertaking for the correctness of information duly
signed by CEO/Managing partner/Managing director
grounds:
active
96. Calco-X Liquid brand name needs to be changed
According to NOTIFCATION F.NO.4-2/2017-DD(H&OTC) in
10years,
Page 7 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
97. Uterus Care Majoon
of or otherwise.
98. Life Red Shot Liquid
of or otherwise.
grounds:
active
99. Bio Care Liquid According to NOTIFCATION F.NO.4-2/2017-DD(H&OTC) in
10years,
100. Life Cool Liquid
of or otherwise.
grounds:
active
101. Life Stomach Liquid brand name needs to be changed
According to NOTIFCATION F.NO.4-2/2017-DD(H&OTC) in
10years,
Page 8 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
grounds:
active
102. Toxy Care Liquid According to NOTIFCATION F.NO.4-2/2017-DD(H&OTC) in
10years,
103. Life Fibro Care Majoon Powder
of or otherwise.
Apple Laboratories, Islamabad
104. I-Coline Syrup
of or otherwise.
105. I-Coline Tablet
of or otherwise.
Atco HealthCare Pvt Ltd, Karachi
106. Numbify Cream
of or otherwise.
Page 9 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
107. Nobloat Oral Drop
of or otherwise.
108. Propilus-S+ Anti Dandruff Lotion Lotion
of or otherwise.
109. Nobloat Oral Solution
of or otherwise.
110. Nobloat Chewable Tablet
of or otherwise.
111. Hydrophil Moisturizing Lotion 20% Lotion
of or otherwise.
Avanza Health Care Pvt Ltd, Lahore
112. Tarocal-D Tablet
of or otherwise.
Page 10 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
Bio Life Enterprises Nutraceuticals, Rawalpindi
grounds:
113. Skipper Capsule  Brand name needs to be changed
 Form 3 needs to be revised w.r.t specification of active
ingredients and signed and stamped
grounds:
 Brand name needs to be changed
114. Algae Cal Sachet
 Monograph of red algae calcium calcium is required
grounds:
115. Sb Berry Sachet  Monograph of red algae calcium calcium is required
 Confirmation of probiotic section
grounds:
116. Ovarifert Sachet  Brand name needs to be changed
grounds:
117. Inn-Bone Junior Sachet
grounds:
118. Bone Save Tablet  Brand name needs to be changed
119. Apday Tablet grounds:
grounds:
120. Inn-Bone Tablet
121. Glutone Tablet grounds:
grounds:
122. Algae Cal Tablet
123. Vitasyn Tablet
Page 11 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
of or otherwise.
Blossom Lab, Pvt, Ltd, Lahore
124. B-Slim Tablet
of or otherwise.
125. Mins-M Tablet
of or otherwise.
126. Gtg-Vit Tablet
of or otherwise.
Calgan Phyto Pharma Pvt Ltd, Lahore
127. Wepatol Tablet grounds:
128. Truvit Tablet grounds:
129. Mama Max Sachet
of or otherwise.
Eon Pharmacy, Karachi
130. Fansud Syrup preparation of their FIFO list, the division has been evaluating and
Page 12 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
of or otherwise.
Etihad Herbal Industries, Lahore
grounds:
131. Ziekuff Syrup
 Evidence of fee submission is required
 brand name needs to be changed
132. Arq-E-Ajwain Syrup
of or otherwise.
133. Chuarqa Syrup
of or otherwise.
134. Arq-E-Badian Syrup
of or otherwise.
135. Arq-Mako Syrup
of or otherwise.
136. Arq-E-Kasni Syrup
of or otherwise.
137. Arq-E-Shahtra Syrup
Page 13 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
of or otherwise.
grounds:
 The applied formulation contains hyaluronic acid and
138. Bonecare Capsule
chondrition sulphate which are in the list of common
molecule
grounds:
139. Ski-E-Sim Syrup
140. Ski-E-Sim Syrup
of or otherwise.
Faisons-Meilleur International (Pvt) Ltd, Lahore
141. Femtill-D Tablet grounds:
grounds:
142. Cartina-Plus Tablet  The applied formulation contains glucosamine,chondrition
sulphate and Hyaluronic acid which is in the list of
common molecule
143. Hi-Cell Tablet grounds:
144. Big Bam Ointment grounds:
Falcon Herbal & Nutraceuticals, Nowshera
grounds:
145. Sharbat-E-Podina Syrup  Properly filled signed and stamped form 3 is required
 Revised form 3 is required w.r.t specification of active
ingredients in the formulation
grounds:
146. Sharbat-E-Pepermint Syrup  Revised form 3 is required w.r.t specification of active
 The applied formulation contains Sodium bicarbonate
which is the list of common molecule
147. Sharbat-E-Faulad Syrup grounds:
Page 14 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
grounds:
148. Sharbat-E-Faulad Sumri Syrup  Properly filled signed and stamped form 3 is required
Ferroza International Pharmaceutical Pvt Ltd, Lahore
149. Ferogut Sachet grounds:
 Confirmation of probiotic section
Filix Pharmaceuticals Pvt. Ltd., Islamabad
150. Testomen Surge Sachet
of or otherwise.
grounds:
151. Rescozyme Q10 Capsule  Properly filled signed and stamped form 3 is required
 Undertaking notarized regarding content and brand name
is required
 Stability studies undertaking is required
Focus & Rulz Healthcare, Islamabad
grounds:
152. Ossmin Suspension
 The applied formulation contains Ossein mineral complex
which is in the list of common molecule
grounds:
153. Serap Forte Tablet
 The applied formulation contains Serratiopeptidase which
is in the list of common molecule
grounds:
154. Ossmin Tablet
 The applied formulation contains Ossein mineral complex
grounds:
155. Serap Ds Tablet
 The applied formulation contains Serratiopeptidase which
is in the list of common molecule
Genetics Healthcare, Lahore
grounds:
156. Zevinc Syrup
 The applied formulation contains Single sulphate as single
ingredient which is in the list of common molecule
157. Celeton Syrup
Page 15 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
of or otherwise.
Global Laboratories Islamabad
grounds:
158. Ovistol Sachet
is required
grounds:
159. Glothione Tablet  Source of proanthycyanidins is required
 Revised form 3 is required w.r.t specification
is required
grounds:
 The applied formulation contains ORS formulation which
160. Globolyte 500Ml Strawberry Solution is in the list of common molecule
is required
grounds:
161. Cod Tablet
is required
grounds:
 The applied formulation contains Sennoside which is in
162. Eascon Tablet the list of common molecule
is required
grounds:
 The applied formulation contains Progesterone which is
163. Rogest Tablet registered as drug
is required
grounds:
164. Glutagen Tablet  Properly filled signed and stamped form 3 is required
is required
Gluck Laboratories Pvt Ltd, Lahore
165. Antacon Plus Syrup
of or otherwise.
Page 16 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
Green Health Nutraceuticals Laboratory, Peshawar
166. Gh Colic Drop
of or otherwise.
Green Which Natural Pharma Pvt. Ltd., Lahore
167. Green'S Hevit-M Tablet
of or otherwise.
168. Green'S Heamo-M Tablet
of or otherwise.
grounds:
169. Win Cal-D Syrup  Brand name needs to be changed
 Differential fee as fee paid for herbal product
grounds:
170. Anir-Vit Tablet
Confirmation regarding the applied products either for
herbal products or Nutraceutical
grounds:
171. Oriange Super Tablet
 Confirmation regarding the applied products either for
grounds:
172. Femiplex Tablet
 The applied formulation contains toxic substance nux
vomica and Hyocyamus niger
173. Green Balm wise arrangement of applications in various designated racks. Since
Page 17 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
of or otherwise.
grounds:
174. U-Plex-M Tablet
 Differential fee as fee paid for herbal product Monograph
of coral calcium is required

grounds:
175. Multiplex Tablet
 The applied formulation contains toxic substance
Hyocyamus niger
grounds:
 The applied formulation contains Iodine which is
registered as a drug
176. G-Dex
grounds:
177. Vet C Drop
 Confirmation regarding the applied products either for
Helix Pharma (Pvt) Ltd, Karachi
178. Danz-Hc Tablet
of or otherwise.
Herbiotics Healthcare, Islamabad
grounds:
179. Bex-D drops
Evidence of fee submission is required
grounds:
180. Nutrigold Tablet
Evidence of fee submission is required
grounds:
181. Multi-S-72 Tablet
 The applied formulation contains magnesium hydroxide
Page 18 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
grounds:
182. Glim-Vit Tablet
grounds:
183. Glim-Max Tablet
grounds:
184. Ironia Syrup
grounds:
185. White-Vit Capsule
grounds:
186. B-Mega Tablet
grounds:
187. Dayvit Tablet
Herbtech Laboratories, Karachi
grounds:
188. Ostcal-D Suspension  Form 3 needs to be revised w.r.t specification of active
ingredients
grounds:
189. Calci4All Drop  Form 3 needs to be revised w.r.t specification of active
ingredients
Himont Laboratories, Lahore
190. Oringa (Mango Sugar Fee)
of or otherwise.
Hizat Nutraceutical Industries, Peshawar
191. Zeecal D Tablet
of or otherwise.
Human Care Laboratories, Peshawar
Page 19 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
192. Human Care'S Xinco Kidz Syrup
of or otherwise.
Inovics Healthcare,Rawalpindi
193. D Need Liquid
of or otherwise.
194. B-Fair Shot
of or otherwise.
195. D-Stone Tablet
of or otherwise.
196. Diabesure Plus Milk Powder
of or otherwise.
197. Femizen Tablet
of or otherwise.
Page 20 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
198. Femoril Capsule
of or otherwise.
grounds:
199. Healise Syrup
 Firm uses herbs in crud form
 Confirmation Of herbal syrup section
200. Tammex Capsule
of or otherwise.
201. Versure Milk Powder
of or otherwise.
202. Zaax Syrup
of or otherwise.
Izfaar Nutraceutical Industries, Lahore
grounds:
203. Vixfar Ointment
Medicom Superior, Lahore
204. Wellgen Ispaghol Sachet
of or otherwise.
Page 21 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
Mediformers Neutraceutical, Lahore
205. Nerogin Syrup
of or otherwise.
Medinoon Research Laboratories, Lahore
grounds:
206. Super Energy Syrup  Brand name needs to be changed
 Clarification regarding salt form of chelated iron is
required
Miksons Healthcare SMC (Pvt) Ltd, Islamabad
207. Cadix Tablet
of or otherwise.
208. H-Vit Tablet
of or otherwise.
209. H-Vit Syrup
of or otherwise.
MSG Nutraceuticals, Islamabad
grounds:
210. Bricks Plus Tablet
grounds:
211. Vitalin Tablet
212. Kuffid Syrup wise arrangement of applications in various designated racks. Since
Page 22 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
of or otherwise.
213. Probo Sachet
of or otherwise.
grounds:
214. Levevit Tablet
 Monograph of Asparagus powder extract is required
grounds:
215. Levegen Tablet  Monograph of Soy Lecithin and Gotu kola powder extract
is required is required
grounds:
216. Levecal Tablet
 Monograph of coral calcium is required
Properly filled signed and stamped form 3 is required
Neutra Cure, Karachi
217. Caplop Tablets
of or otherwise.
218. Vagicare Tablet
of or otherwise.
Nutrabiotics Nutritional Life Sciences, Peshawar
grounds:
219. Ocuaid Pllus Tablet ingredients
 Clarification required regarding use of bilbeery and either
used in crude or extract form
Page 23 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
grounds:
220. Ocuaid Plus Syrup ingredients
 Clarification required regarding use of bilbeery and either
used in crude or extract form
Nutrasource International, Karachi
grounds:
 Firm uses herbs in crude form
 Confirmation of herbal syrup section
 Confirmation about applied product either herbal or
221. Digxil-H Suspension
nutraceutical Fee paid off herbal product and remaining
fee is required
 The applied formulation contains toxic plant Berberis
vulgaris
grounds:
222. Eatall Syrup
fee is required
grounds:
223. Hicid Suspension
fee is required
 The applied formulation contains sodium bicarbonate
grounds:
224. Icecid Suspension
fee is required
grounds:
225. Kuftec Syrup
fee is required
Nutrimake Laboratories, Lahore
grounds:
226. Multi Zinc Tablet
Page 24 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)

grounds:
227. Multiwait Syrup
grounds:
228. Multiwait Tablet
grounds:
229. Glucowait Tablet
 The applied formulation contains Glucosamine sulphate
and Chondroitin sulphate which are in the list of common
molecule
grounds:
230. Sythin-Z Tablet
Pakistan Pharmaceutical Products Pvt Ltd, Karachi
grounds:
231. Sleeppill (Melatonin) 2Mg Tablet  The applied formulation contains Melatonin which is in
the list of common molecule
grounds:
grounds:
grounds:
234. Glycifer Tablet
 Revised form 3 required w.r.t to specification
grounds:
235. Acid Gone Suspension  Brand name needs to be changed
grounds:
236. Serrazen Forte Tablet
 The applied formulation contains Serrapeptase which is in
PDH Health Care, Lahore
237. Skinclear Cream
of or otherwise.
Page 25 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
Rayyon Skin & Healthcare, Karachi
238. Ack-Derm Soap
of or otherwise.
239. Ol Vee Soap
of or otherwise.
Scilife Pharma, Karachi
240. Scifol 400Mcg Tablet
of or otherwise.
Scotmann Pharmaceutical, Islamabad
grounds:
 The applied formulation contains Melatonin which is in
241. Melaton 3Mg Tablet the list of common molecule
is required
grounds:
242. Melaton 5Mg Tablet the list of common molecule
is required
grounds:
243. Melaton Sr 2Mg Tablet the list of common molecule
is required
grounds:
244. Sunnycal Tablet
is required
Page 26 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
grounds:
245. Melaton Plus Tablet the list of common molecule
is required
Sindhco Nutraceuticals, Kasur
grounds:
246. Colimin Syrup  Firm uses herbs in crude form
 Clarification regrading herbal syrup section is required
grounds:
247. Colimin Drop
 Clarification regrading herbal oral liquid section is
required
248. N-Zyme Syrup grounds:
The Best Laboratories Lahore
249. Denorate Forte Drops
of or otherwise.
Trends Pharmaceuticals Lahore
grounds:
250. Era Plus Tablet
Verbana International, Islamabad
251. Fitfat Powder
of or otherwise.
grounds:
252. V-Tox Powder
253. Pro Fat Powder
Page 27 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
of or otherwise.
254. Cowtin Powder
of or otherwise.
Vermon Nutraceutical Pvt Ltd, Lahore
grounds:
255. Gasrite Syrup  Brand name needs to be changed
 Revised form 3 w.r.t speciation of active ingredient is
required
grounds:
256. G-Fate Syrup  Revised form 3 w.r.t speciation of active ingredient is
required
 Clarification of herbal syrup section
grounds:
257. Gaspo-Nil Syrup  The applied formulation contains sodium bicarbonate
required
grounds:
258. Vermon Dyrol Syrup  Clarification of herbal syrup section
required
grounds:
259. Vermon Podina Syrup  Clarification of herbal syrup section
required
grounds:
260. Pipper Mint Syrup  Revised form 3 w.r.t speciation of active ingredient is
required
grounds:
261. Leeco'S Flunac Syrup
Page 28 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
required
grounds:
262. Cofnex Syrup  Brand name needs to be changed
required
grounds:
263. Vermon Antacid Syrup  Brand name needs to be changed
required
264. Leeco'S Rd Cough Syrup grounds:
grounds:
265. Big-Cran Pouches  Firm uses herbs in crude form
 Proof of sachet general section
grounds:
266. Gink-Sr Syrup
required
grounds:
267. Ginvit Syrup
grounds:
268. Vermon Fast Blood Syrup  Brand name needs to be changed
required
grounds:
269. Mvita-X Syrup  Brand name needs to be changed
required
Weather Folds Hattar
grounds:
270. Vacinum Sachet  Brand name needs to be changed
required
Wilson's Healthcare, Islamabad
grounds:
271. Wilson'S Fizzy Blackberry 10Mg Tablet
 Undertaking regarding content and brand name is required
grounds:
272. Wilson'S Fizzy Orangia 10Mg Tablet
273. Wilson'S Fizzy Pomegranate 10Mg Tablet grounds:
Page 29 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
of or otherwise.
grounds:
275. Wilson'S Fizzy Orangia 50Mg Tablet
grounds:
276. Wilson'S Fizzy Pomegranate 50Mg Tablet
grounds:
278. Wilson'S Osteofiz (Orange) Tablet
of or otherwise.
279. Wilson'S Fizzy Orangia 50 Tablet
of or otherwise.
grounds:
280. Wilson'S Fizzy Strawberry 50 Tablet
281. Wilson'S Osteofiz (Mango) Tablet
of or otherwise.
282. Wilson'S Fizzy Cola 50Mg Tablet grounds:
Page 30 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
Adcok Pharmaceutical (Pvt) Ltd, Lahore
Deferred for following reasons:
Rylo-Ad Drops  Fee evidence is required alongwith R & I receiving
evidence.
283.
 Form 3 is required.
 Brand name undertaking and content undertaking are
required.
 Fee evidence is required alongwith R & I receiving
evidence.
284. Fancid Syrup
required.
evidence.
285. Zixvy Syrup
required.
286. Gaxry Tablet Deferred for submission of Signed and stamped Form 3.
evidence.
287. Ilmf Tablet
required.
evidence.
288. Orbitol Syrup
required.
evidence.
289. Oxita Tablet
required.
Alfalah Health Care (Pvt) Ltd Lahore
evidence.
290. Levo Cid Syrup
required.
evidence.
291. Ivysip Syrup
required.
evidence.
292. Prevocid Syrup
required.
293. Vitlife Tablet Deferred for following reasons:
Page 31 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
evidence.
required.
evidence.
294. Promom Advance Tablet
required.
evidence.
295. Maxman Tablet
required.
evidence.
296. Alvo-Cal Tablet
required.
evidence.
297. Spremax Tablet
required.
evidence.
298. Ovegen Tablet
required.
evidence.
299. Healfer Tablet
required.
Angel Human Health Nutraceutical, Faisalabad
evidence.
300. Hizer Syrup
required.
evidence.
301. Valta Tablet
required.
302. Cran-X Syrup
evidence.
Page 32 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
required.
evidence.
303. Kidz-Ad Drop
required.
evidence.
304. Ko-Line Tablet
required.
evidence.
305. Immunovit Syrup
required.
evidence.
306. Hi-Roz Tablet
required.
evidence.
307. Lemacule Tablet
required.
evidence.
308. Iconate-Fa Tablet
required.
evidence.
309. Dia-Beta Plus Tablet
required.
evidence.
310. Folixa-N Tablet
required.
evidence.
311. Xeetonin Drop
required.
312. Bvita-Da Drop  Fee evidence is required alongwith R & I receiving
evidence.
Page 33 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
required.
Deferred for change of brand name and submission of Fee evidence
313. Spasminil Drop
of spasminil drop.
314. Invecal Syrup Deferred for submission of Fee evidence of invecal syrup
315. Folixa Plus Tablet Deferred for submission of Fee evidence of folixa plus tablet.
evidence.
316. Nutriwin Tablet
required.
evidence.
317. Cocarti Tablet
required.
evidence.
318. Contacool Syrup
required.
evidence.
319. Enzic Tablet
required.
evidence.
320. Nutriwin Syrup
required.
Animal Life Care, Bahawalpur
Deferred for submission of monograph of hydrargyry
321. Life Fibro Care Majoon
subchloridum.
322. Anza Pharma, Lahore
evidence.
323. Profer Plus Sachet
required.
evidence.
324. Antacon Soda Sachet
required.
325. C-Well Grow Oral Drop Deferred for change of brand name.
326. C-Well M Oral Drop Deferred till finalization of common molecules list.
327. C-Well D Oral Drop Deferred for change of brand name.
328. C-Well AD Oral Drop Deferred for change of brand name.
329. C-Well BG Oral Drop Deferred till finalization of common molecules list.
330. C-Well Grow Syrup Deferred for change of brand name.
Page 34 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
331. Coral+ Tablet Deferred for change of brand name.
evidence.
332. Brotis Oral Drops
required.
Avant Pharmaceutical, Karachi
333. Inglot-D Syrup Deferred for submission of Signed and stamped Form 3.
evidence.
334. Avezinc Syrup
required.
335. Inglot-D Tablet Deferred for submission of Signed and stamped Form 3.
Bio Life Enterprises Nutraceuticals, Rawalpindi
336. Furty-X Capsule
 Monographs of chlorophytum borivillanum and emblica
officinalis are required.
evidence.
337. Glo+ Capsule
required.
Deferred for following deficiencies:
338. Ainfar-X Plus Capsule  Brand name needs to be changed.
 Yohimbine is added in common molecules list.
evidence.
339. Boneeta+ Tablet
required.
Deferred for submission of monographs of malus domestica and
340. Forliv Tablet fragaria and Firm applied same formulation in same dosage form
under different brand name, needs clarification in this regard.
Deferred for submission of monographs of malus domestica and
341. Heplay Tablet fragaria and Firm applied same formulation in same dosage form
under different brand name, needs clarification in this regard.
342. PCOS-Fix Tablet Deferred for change of brand name.
Bio Serve Pharma, Karachi
343. Cranbest Sachet Deferred for change of brand name.
evidence.
344. Hederaser Plus Syrup
required.
evidence.
345. Servegin Syrup
required.
346. Hederaser Syrup Deferred for following reasons:
Page 35 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
evidence.
required.
evidence.
347. Glucoserve Tablet
required.
348. Hivit Tablet Deferred for change of brand name.
Biotron Altair Pakistan, Karachi
evidence.
349. Electrolade Sachet
required.
350. Lactyd Drop Deferred till finalization of common molecules list.
 Signed and stamped form 3 is required.
351. Biotron Gripe Water  Brand name change and contents undertakings are
required.
 Fee evidence is required.
352. Emty Syrup Deferred till finalization of common molecules list.
353. Drip Drop ORS Sachet Deferred till finalization of common molecules list.
Bless Laboratories Pvt. Ltd., Lahore
evidence.
354. D-Ferb Syrup
required.
evidence.
355. Hizyme Syrup
required.
evidence.
356. Glovit Syrup
required.
Burj Healthcare, Karachi
357. Ovit M Soft Gelatin Capsule  Availability of softgel capsule section is required.
 GMP compliance report is required.
Deferred till submission of GMP compliance report and change of
358. Everplan Sachet
brand name..
359. Gerifex Syrup Deferred till submission of GMP compliance report.
360. Ovit M Syrup
evidence.
Page 36 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
required.
Deferred for change of brand name and submission of GMP
361. Foligain Tablet
compliance report.
Cidex Laboratories, Peshawar
Deferred for submission of stability of omega 3 in tablet dosage
362. Welmeg Tablet
form.
evidence.
363. Mactorfer Tablet
required.
Eon Pharmacy, Karachi
Deferred due to following reasons:
 Firm applied fee of Neocal Vit D syrup while Submitted
364. Neocal Vit D Syrup
Form 3 is of Neo-Calvit Syrup, needs clarification in this
regard. Brand name needs to be changed in either case.
365. Calceon Syrup Deferred for change of brand name.
366. Multeon Syrup Deferred for change of brand name.
Etihad Herbal Industries, Lahore
367. Solar Capsule  Form 3 to be signed by CEO/owner and stamped.
 Silymarin is added in common molecules list.
368. Liver Age Syrup
 Form 3 to be signed by CEO/owner and stamped.
 Monograph of cardus marianus extract is required.
Faisons-Meilleur International (Pvt) Ltd, Lahore
369. Cam-D Tablet Deferred for change of brand name and submission of fee evidence.
370. Vitanol Gold Tablet  Individual strength of lutein and zeaxanthin are required.
 Stability of DHA (omega 3) in tablet dosage form is
required.
Deferred since fee challan is not endorsed by concerned division of
371. Nucran Sachet
DRAP and change of brand name.
evidence.
372. Pepsid Syrup
required.
evidence.
373. Ovi-Safe Sachet
required.
evidence.
374. Life Shine Tablet
required.
Deferred till finalization of common molecules list and change of
375. Ortho-Fact Tablet brand name and Fee challan is not endorsed by concerned division
of DRAP.
376. Calwell Sachet Deferred for following reasons:
Page 37 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
 Monograph of red algae calcium is required.
 Brand name needs to changed.
Deferred since Fee challan is not endorsed by concerned division of
377. Q-Fenz 10 Tablet
DRAP.
Focus & Rulz Healthcare, Islamabad
evidence.
378. Serap Tablet
required.
Galen Nutraceuticals, Islamabad
evidence.
379. Mint-G
required.
Genetics Healthcare, Lahore
Deferred for submission of monograph of pelargonium sidoides
380. Preus Tablet
extract.
Greektec Nutraceutical, Karachi
evidence.
381. Fertizyme Tablet
required.
Helix Pharma (Pvt) Ltd, Karachi
382. Danz-Q Tablet Deferred till finalization of common molecules list.
Herbiotics Healthcare, Islamabad
Deferred since Firm has submitted two files with same brand name
383. Chest Best Syrup
having different formulations, needs clarification in this regard.
384. Humpty Dumpty Syrup Deferred for change of brand name.
385. Ceze-D Plant Tablet
having different formulations, needs clarification in this regard
386. Sugnovit Tablet
Deferred since Fee challan is not endorsed by concerned division of
387. Anzer Plus Syrup DRAP and Firm has submitted two files with same brand name
388. Tribmax Tablet Deferred till finalization of common molecules list.
389. Sernol Tablet Deferred for submission of monograph of raspberry ketone.
390. Stro-M Tablet Deferred till finalization of common molecules list.
391. Medigreen Folic Acid Tablet
having different formulations, needs clarification in this regard.
Hinucon, Karachi
evidence.
392. Pixel Combi Capsule
required.
evidence.
393. Pixel C Chewable Tablet
required.
Page 38 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
394. Fibocell Powder Deferred for submission of availability of probiotic section.
Hisun Pharmaceutical Industries, Swabi
evidence.
395. Krone-12 Tablet
required.
evidence.
396. Hemukon Tablet
required.
evidence.
397. Orivamin Syrup
required.
evidence.
398. Mayokon Sachet
required.
evidence.
399. Orivamin Tablet
required.
Izfaar Nutraceutical Industries, Lahore
evidence.
400. Brosis Gold Plus Capsule
required.
evidence.
401. Soda-H2 Powder
required.
evidence.
402. Super Stem Liquid
required.
evidence.
403. Vimin Plus (Vet)
required.
404. Trilong Capsule Deferred for following reasons:
Page 39 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
evidence.
required.
evidence.
405. Trisom Capsule
required.
evidence.
406. Enufmom Powder
required.
evidence.
407. Livofar Capsule
required.
evidence.
408. Memogen Syrup
required.
King Camco Pharma Nutraceutical, Lahore
409. Bestrine Mouthwash Deferred till finalization of common molecules list.
410. Bon-Cal D Tablet Deferred for change of brand name.
411. Kamcid Plus Syrup Deferred for change of brand name.
412. Bon Calacter Tablet Deferred for change of brand name.
Deferred since Application is devoid of following deficiencies:
 Form 3 is un-signed and un-stamped.
413. Folic Plus Tablet  Contents and brand name change undertakings are
required.
evidence.
414. Active Bone Tablet
required.
evidence.
415. La-Cid Syrup
required.
evidence.
416. Clean Cough Syrup
required.
Mazton Pharmaceuticals, Lahore
417. Kelo-Cote Gel Deferred for following reasons:
Page 40 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
evidence.
required.
Medicom Superior, Lahore
418. Curqu-Max Tablet Deferred for change of brand name.
419. Pregna-Mate Tablet Deferred for change of brand name.
420. Biocal+D Tablet  Monograph of red algae calcium is required.
421. Vita-Gold Tablet Deferred for change of brand name.
Deferred for submission of Monograph of eurycoma longifolia
422. Men’S Gold Capsule
extract and change of brand name.
Deferred till finalization of common molecules list and change of
423. Ortho-Plus Tablet
brand name.
424. Bright Start Drop Deferred for change of brand name.
Miksons Healthcare SMC (Pvt) Ltd, Islamabad
evidence.
425. Hepato Syrup
required.
evidence.
426. Q-Nit Tablet
required.
evidence.
427. Vitm-F Syrup
required.
428. Mind blow Syrup Deferred till finalization of common molecules list.
evidence.
429. Milci-Cal Tablet
required.
430. Oscan Tablet Deferred for change of brand name.
evidence.
431. Ferosan Syrup
required.
432. Epimax Syrup Deferred for change of brand name.
evidence.
433. Calfomix Tablet
required.
434. Methyl-F Tablet Deferred for following reasons:
Page 41 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
evidence.
required.
evidence.
435. Mikson-D Drop
required.
evidence.
436. Convit-3 Tablet
required.
Mod Herbs, Karachi
evidence.
437. Kidnifit Tablet
required.
evidence.
438. Marex-G Tablet
required.
evidence.
439. Moplus Capsule
required.
evidence.
440. Timin-P Capsule
required.
evidence.
441. Dayfun-3 Tablet
required.
evidence.
442. Nerbest Tablet
required.
443. Maca Man Sachet
evidence.
Page 42 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
required.
evidence.
444. Marex-G Syrup
required.
evidence.
445. Livcap-S Tablet
required.
evidence.
446. Nerbest Syrup
required.
evidence.
447. Livcap-S Syrup
required.
evidence.
448. Minvit Syrup
required.
Montis (Pvt) Ltd, Lahore
evidence.
449. Kraze Moisturizing Cream
required.
evidence.
450. Prozinc Clean Shampoo
required.
evidence.
451. Ban Sun Sc Spf 40 Gel
required.
MSG Nutraceuticals, Islamabad
452. Floline Syrup Deferred for submission of signed and stamped Form 3
453. Encim Tablet Deferred for submission of Stability of omega 3 in tablet.
Novamed Healthcare, Lahore
Deferred for submission of Form 3 to be signed by owner/ CEO of
454. Avelia Tablet
firm.
Nutrasource International, Karachi
455. Lexicof Syrup Deferred for following reasons:
Page 43 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
 change of brand name and submission of differential fee.
 Availability of herbal section is required.
Deferred for change of brand name and submission of differential
456. Mukaim Suspension
fee.
evidence.
457. Pakcid Suspension
required.
Deferred for change of brand name and submission of differential
458. Saracid Suspension
fee.
Deferred for change of brand name, submission of differential fee
459. Unicid Suspension
and till finalization of common molecules list.
460. Liskovit-M Syrup Deferred for change of brand name.
Nutrifactor Laboratories (Pvt) Ltd, Faisalabad
461. Cufex Syrup Deferred for change of brand name.
462. Neutral Syrup Deferred for change of brand name.
Nutrimed Laboratories, Karachi
463. Ironax Syrup Deferred for change of brand name.
464. Ironac Tablet Deferred for change of brand name.
465. Toux Drops Deferred for change of brand name.
Deferred for submission of Monographs of all ingredients in extract
466. Bonaq Drops
form.
Nutrix Health Care, Faisalabad
evidence.
467. Flurex Sachet
required.
 Evidence of safety profile of Sambuscus nigra is required.
468. Flurex Syrup
 Monographs of echinacea purpurea, pinus pinaster extract,
lavendulan angustifolia are required.
 Evidence of safety profile of Sambuscus nigra is required.
469. Flurex Tablet
 Monographs of echinacea purpurea, pinus pinaster extract,
lavendulan angustifolia are required.
evidence.
470. Hepsil Suspension
required.
471. Jyf-Zar Syrup Deferred for submission of monograph of apple extract.
472. Nix Syrup  Contents and brand name change undertakings are
required.
473. Xeebon Plus Tablet  Contents and brand name change undertakings are
required.
474. Chol-D Stat Soft Capsule  Fee evidence is required alongwith R & I receiving
evidence.
Page 44 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
required.
evidence.
475. Foliks Soft Capsule
required.
evidence.
476. Multi-G Soft Capsule
required.
evidence.
477. Bone-D Soft Capsule
required.
evidence.
478. Reox Soft Capsule
required.
evidence.
479. White Cal-D Soft Capsule
required.
evidence.
480. Bone-D Soft Capsule
required.
evidence.
481. Chol-D Stat Soft Capsule
required.
evidence.
482. Mutli-G Soft Capsule
required.
483. E-Day Soft Capsule Deferred for change of brand name.
evidence.
484. Caltrum Soft Capsule
required.
485. Foliks Soft Capsule Deferred since Application is devoid of following deficiencies:
Page 45 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
 Contents and brand name change undertakings are
required.
486. Pinq-D Suspension  Contents and brand name change undertakings are
required.
Oasis Pharma, Lahore
487. Osilite (Oral Electrolyte Solution) Liquid Deferred till finalization of common molecules list.
 Firm submitted fee of Pefcect sachet (probiotic) while
submitted Form 3 is of calcee plus sachet, needs
clarification in this regard.
488. Pefcect Sachet
 Firm has changed formulation from probiotic to vitamins.
In this regard, if firm intends to change formulation then
firm is required to submit new application along with
prescribed fee.
Olio Pharma Inc, Lahore
evidence.
489. Men’S Formula Tab Tablet
required.
evidence.
490. Women’S Formula Tab Tablet
required.
evidence.
491. Vigomate Capsule
required.
Opal Laboratories, Karachi
Deferred for submission of Form 3 to be signed by CEO/owner of
492. Ven-Berrry Sachet
company.
Paksons Neutro, Kabirwala
493. Nausenil Plus Syrup Deferred till finalization of common molecules list.
494. Hair Folligen Tablet Deferred for change of brand name.
495. Appisure Syrup Syrup  Brand name needs to be changed.
 Monograph of cuminum cymium extract is required.
evidence.
496. Plexyfer Syrup
required.
Paragon Herbal Laboratories, Lahore
497. Calci-Loc Tablet Deferred for change of brand name.
Parina Pharma Pvt Ltd, Karachi
498. Colinor Stick
 Monograph of orafti GR in required.
Page 46 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
 Manufacturing process of stick and in which section it
will be formulated as dosage form, is required.
499. Poly+Aid Ointment Deferred for change of brand name.
evidence.
500. Mukaim (Strawberry) Syrup
required.
evidence.
501. Gum Safe Solution
required.
Pharma International, Karachi
evidence.
502. Ginsana G115 Capsule
required.
Phytotia Laboratory, Peshawar
evidence.
503. Calcfit Tablet
required.
evidence.
504. Kemivit Tablet
required.
evidence.
505. Orthomax-D Tablet
required.
evidence.
506. Calmax Tablet
required.
evidence.
507. Ferimax Tablet
required.
evidence.
508. Vitsmax Tablet
required.
Page 47 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
evidence.
509. Locid Syrup
required.
evidence.
510. Herbecough Syrup
required.
Polyfine Nutra-Sciences, Peshawar
evidence.
511. Carol-D Tablet
required.
evidence.
512. Circarest Tablet
required.
evidence.
513. Silycolin Tablet
required.
evidence.
514. Glucomin Plus Tablet
required.
evidence.
515. Enforta Capsule
required.
QH Health (Private) Limited, Karachi
evidence.
516. Trick-D Junior Oral Drop
required.
evidence.
517. Folift 300Mg Tablet
required.
Royal Laboratoies Lahore
518. Pimvit-G Tablet Deferred for following reasons:
Page 48 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
evidence.
required.
519. Nomin Drop Deferred till finalization of common molecules list (melatonin).
Saviour Pharma, Lahore
Deferred for submission of Monographs of phaseolulus vulgaris
520. Shapes Tablet
extract and garcinia gambogia extract and change of brand name.
521. Step-10 Tablet Deferred for change of brand name.
Scotmann Pharmaceutical, Islamabad
522. Sun-D 5000IU Tablet Deferred for submission of Signed and stamped Form 3.
Sefon Pharma, Sargodha
 Firm submitted fee of hepatonic plus liquid while
523. Epatonic Plus submitted form 3 is of Epatonic plus liquid, needs
clarification in this regard. Brand name needs to be
changed in either case.
524. Lactomin Gold
 Strength of all ingredients per serving dose is required.
Deferred for change of brand name and Strength of all ingredients
525. Livosef Extra Powder per serving dose is required.

 Monographs of gypsum fibrosum and prunus dulcis
526. Pulmopoul Super Liquid extract are required.
 Strength of all ingredients per serving dose is required.
527. Coolant-C liquid  Strength of all ingredients per serving dose is required.
528. Coolant C4T Liquid  Strength of all ingredients per serving dose is required.
Selmore Agencies (Pvt) Ltd, Lahore
evidence.
529. Covtec Liquid
required.
evidence.
530. Rendo-S
required.
evidence.
531. Phopholigo Liquid
required.
evidence.
532. No Heat-S Soluble Powder
required.
Page 49 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
evidence.
533. Bio-Berry Liquid
required.
evidence.
534. Cidotec Liquid
required.
evidence.
535. C-Star
required.
evidence.
536. Viba Zone
required.
evidence.
537. Biogen-S Soluble Powder
required.
evidence.
538. Pacom-A
required.
evidence.
539. Pacomcid
required.
evidence.
540. Paravita Liquid
required.
evidence.
541. Vitro-S
required.
542. Liversol
evidence.
Page 50 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
required.
evidence.
543. Biogen
required.
SHS Nutrition, Karachi
evidence.
544. Acti Life M 50+ Tablet
required.
evidence.
545. Acti Life M Capsule
required.
evidence.
546. Pregnable M Tablet
required.
evidence.
547. Foliwell Tablet
required.
evidence.
548. Stimulinds Capsule
required.
evidence.
549. Acti Life F Capsule
required.
evidence.
550. Proganycare Capsule
required.
evidence.
551. Pregnable F Tablet
required.
552. Stimulin Ds Capsule Deferred for following reasons:
Page 51 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
evidence.
required.
evidence.
553. Acti-Joint Tablet
required.
evidence.
554. Bonniecare Capsule
required.
evidence.
555. Acti Life F 50+ Tablet
required.
evidence.
556. Bonniecare Capsule
required.
evidence.
557. Bonniecare Tablet
required.
evidence.
558. Joggle Box Tablet
required.
evidence.
559. Bonetab Tablet
required.
Sigma Pharma International, Karachi
evidence.
560. Nb Cranberry Fruit 4200Mg Plus Vitamin C
required.
561. Nb Ginko Biloba 60Mg Capsule
evidence.
Page 52 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
required.
evidence.
562. Nb 5-Htp 100Mg Capsule
required.
Simbro HealthCare, Lahore
evidence.
563. Meth-D Tablet
required.
564. Brocal Tablet Deferred for change of brand name.
565. CSH Late Tablet  Glucosamine is added in common molecules list.
566. Csh-Zcal Tablet  Contents and brand name change undertakings are
required.
567. Calzinc Tablet Deferred for change of brand name.
568. Zycolate Tablet Deferred till finalization of common molecules list.
Sois Life Sciences, Karachi
evidence.
569. Irowin Drop
required.
evidence.
570. Zinglu Syrup
required.
evidence.
571. Stall-D Drop
required.
evidence.
572. Osteogel Cream
required.
evidence.
573. Elett Syrup
required.
574. Bonform Sachet Deferred for following reasons:
Page 53 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
evidence.
required.
evidence.
575. Mefol-Dha Soft Gelatin Capsule
required.
evidence.
576. Maximize Syrup
required.
evidence.
577. Liverwin Syrup
required.
evidence.
578. Iv-Mint Syrup
required.
579. Calwin-X Tablet Deferred for change of brand name.
evidence.
580. Crany Sachet
required.
evidence.
581. Fat Burn Capsule
required.
evidence.
582. Folica-400 Tablet
required.
evidence.
583. Ivy-Dm Syrup
required.
584. Active-8 Tablet
evidence.
Page 54 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
required.
evidence.
585. Deep Relief Gel
required.
evidence.
586. Cubex Tablet
required.
evidence.
587. Q-Role Plus Soft Gelatin Capsule
required.
588. Growin Syrup Deferred for change of brand name.
evidence.
589. Sunfit D Soft Gelatin Capsule
required.
evidence.
590. Hydrobiotic Sachet
required.
591. Wintacid Suspension Deferred till finalization of common molecules list.
evidence.
592. Bemalt Syrup
required.
evidence.
593. Cal Win-X Syrup
required.
594. Befolic Tablet Deferred for change of brand name.
595. Pure Folic Soft Pearls Capsule Deferred for change of brand name.
596. Pure Multi Vitamins Tablet Deferred for change of brand name.
597. Pure Calcium Tablet Deferred for change of brand name.
598. Co Active Tablet Deferred for change of brand name.
599. Pure Epo Soft Gelatin Capsule Deferred for change of brand name.
Deferred for Availability of food supplement section and change of
600. Aminovit Sachet
brand name.
Syncar Nutraceuticals, Rawalpindi
601. Neohope Syrup Deferred for change of brand name.
602. Cough B Syrup  Fee evidence is required alongwith R & I receiving
evidence.
Page 55 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
required.
Tehseen Industries, Lahore
 Signed and stamped Form 3 is required.
603. Meco D’S Tablet
 N-acetyl cysteine is added in common molecules list.
Tarrot Health Care, Lahore
evidence.
604. Max Natural Plus Sachet Sachet
required.
evidence.
605. Dee-Drops Drops
required.
evidence.
606. Ad More Drops Drops
required.
Theramed Healthcare, Lahore
evidence.
607. Huskit-C
required.
Trends Pharmaceuticals Lahore
evidence.
608. Hepa-Q Syrup
required.
609. Spasgon Tablet Deferred for submission of monograph of basil.
evidence.
610. Hi-Zar Milk Sachet
required.
611. Mabso Iron Syrup  Brand name change and contents undertakings are
required.
612. Mabsocaltrat D Tablet  Brand name change and contents undertakings are
required.
Page 56 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)

613. Mabsopreg Tablet  Brand name change and contents undertakings are
required.
614. Mom Milk Sachet  Strength of all ingredients per serving dose is required.
615. Nutracal-D Sachet Deferred for change of brand name.
616. Ener-G Tablet Deferred till finalization of common molecules list.
617. Qukuf +Syrup Deferred for change of brand name.
evidence.
618. Allfixit Tablet
required.
 Brand name change and contents undertakings are
619. Gusto Syrup
required.
620. Vitashine Syrup Deferred for change of brand name.

evidence.
621. Glomom Sachet
required.
Deferred due to following reasons:
 Beta sitosterol is added in common molecules list.
622. Mabcentrum Specialist Tablet  Monograph of stinging nettle root extract and pygeum
amricanum extract are required.
623. Vitashine Tablet Deferred for change of brand name.

Vermon Nutraceutical Pvt Ltd, Lahore
624. Malt-C Tablet
required.
625. Myositol-F Tablet Deferred for change of brand name.

626. Unical Tablet Deferred for change of brand name.
627. Bull Kraft Tablet Deferred for change of brand name.
evidence.
628. Osteo-D Tablet
required.
evidence.
629. Mega-Fol Tablet
required.
Page 57 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
evidence.
630. Citra Tablet
required.
631. Bon-Z Tablet Deferred for change of brand name.
632. Ostco-D Tablet
633. Bon-Z Tablet
634. Mysoitol-F Tablet
Vida Laboratories, Karachi
evidence.
635. Preymalt Tablet
required.
evidence.
636. Perymalt-F Tablet
required.
 Strength of elemental iron in iron (III) hydroxide
637. Perymalt Syrup polymaltose complex is required.
 Monograph of iron (III) hydroxide polymaltose complex
is required.
638. Vidacoline Syrup Deferred till finalization of common molecules list.
639. Vidacoline 500Mg Tablet Deferred till finalization of common molecules list.
Deferred for submission of Safety profile of sambuscus nigra
642. Relivac Plus Sachet extract is required since it is toxic (contains cyanogenic acid) and
submission of monograph of purple coneflower extract.
Deferred for submission of Safety profile of sambuscus nigra
643. Relivac Sachet
extract is required since it is toxic (contains cyanogenic acid).
Deferred for submission of Individual Strength of lutein and
644. Ocutin 40Mg Soft gel Capsule
zeaxanthin.
Deferred for submission of Individual Strength of lutein and
645. Ocutin 20Mg Capsule
zeaxanthin.
646. Fevifol-D Sachet  Brand name change and contents undertakings are
required.
647. Glutamax Tablet
evidence.
Page 58 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
required.
648. Covitak Softgel
required.
649. Cokrill Plus Capsule Deferred for submission of monograph of krill oil.
650. Cokrill Softgel Deferred for submission of monograph of krill oil.
Vital Mark Laboratories Pvt Ltd, Fasialabad
651. Vital Milk Grow powder  Justification of term by-pass fat and its use is required.
Deferred with following deficiencies:
 Clarification of term organic acid required.
652. Tox Noll Plus Powder  Monograph of yeast cell wall is required.
 Justification of use of activated charcoal is required.
 Clarification of herbal extract and organic acids are
653. Vital Tox Noll Powder
required.
 Monograph of humic acid is required.
Wilson's Healthcare, Islamabad
evidence.
654. Wilson'S Hi-C-Vita (Pomegranate)
required.
evidence.
655. Wilson'S 3-Bion
required.
evidence.
656. Wilson'S Hi-C-Vita (Orange)
required.
evidence.
657. Wilson'S Hi-C-Vita (Cola)
required.
evidence.
658. Wilson'S Aqua-Saline Nasal
required.
659. Wilson'S Hi-C-Vita (Pomegranate)
evidence.
Page 59 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
required.
evidence.
660. Wilson'S Hi-C-Vita (Red Grapes)
required.
evidence.
661. Wilson'S Hi-C-Vita (Strawberry)
required.
evidence.
662. Wilson'S Hi-Ckd (Orange)
required.
evidence.
663. Wilson'S Hi-Ckd (Cola)
required.
evidence.
664. Wilson'S Hi-Ckd (Red Grapes)
required.
evidence.
665. Wilson'S Acrowil (Orange)
required.
evidence.
666. Wilson'S Hi-Ckd (Strawberry)
required.
evidence.
667. Wilson'S Hi-C-Vita (Orange)
required.
evidence.
668. Wilson'S Hi-C-Vita (Strawberry)
required.
669. Wilson'S Hi-C-Vita (Cola)  Fee evidence is required alongwith R & I receiving
evidence.
Page 60 of 61
F.No.10-07/2021-OTC) (M-91)

(1) (2) (3)
required.
evidence.
670. Wilson'S Hi-C-Vita (Red Grapes)
required.
evidence.
671. Wilson'S Acrowil (Orange)
required.
M/s Adcok Pharmaceutical (Pvt) Ltd,
Plot No 3-3-km, Defence off Raiwind Road ,Near Lahore Univerisity Lahore
672. Sentia mouthwash Deferred for further deliberation.
673. Lister Antisptic mouthwash Deferred for further deliberation.
674. Protack mouthwash Deferred for further deliberation.
Falcon Laboratories (Pvt.) Limited, (E. No.00710)
Special Industrial Estate, Behind Industrial Estate Office Risalpur, Nowshera
675. Neuroline Syrup
of brand name.
(Ayyaz Ahmad)
Secretary, Enlistment Evaluation Committee
Page 61 of 61
F.No.10-07/2021-OTC) (M-91)
ANNEXURE
The firm is directed to submit soft data in both
MS Excel & MS Word on following formats in
USB ONLY.
MS Excel Format
Sr. Company Product Dosage Composition Common Recommended Pack Date of R&I
No. name Name Form name use Size submission
1. (Company XYZ Tablet Each tablet XXX XXX 10’s DD.MM.YYYY
name, City) contains: 20’s
Without Abc
address (USP)...50mg
2.
MS Word Format
Company Product Name and Common Pack
Sr. No. Recommended use
name composition name Size
1. (Company XYZ Tablet XXX XXX 10’s
name, City) Each tablet contains: 20’s
Without Abc (USP)….50mg
address
2.
Page 62 of 61

Deficiency Letter of All Deferred Products in 91st Meeting of EEC Held On 13 07 2021

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Deficiency Letter of All Deferred Products in 91st Meeting of EEC Held On 13 07 2021

Uploaded by

Copyright:

Available Formats

F.No.

Islamabad, the 21st October, 2021

Subject: Submission of deficient information / documents

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

EEC decided to deferred the application for enlistment on following

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

EEC decided to deferred the application for enlistment on following

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

Deferred for following reasons:

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

S.No Brand name Decision

Deferred for following reasons: